Home / ABEO : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ABEO make money? Does ABEO have pricing power? What's the Earnings Whisper? Will ABEO profit more as the business scales? What is ABEO's management track record? Is ABEO's current price justified?

Abeona Therapeutics Inc.

$5.47 +$0.16 (+3.02%)

NASDAQ · 14 Sep 2026 16:29 UTC

Previous Close

$5.42

Day Range

$5.37$5.52

Year Range

$4$7.65

Market Cap

311.79M

AVG Volume

1.33M

Trailing/Forward PE

-4.81/-

PEG ratio

0.06

Dividend Yield

Next Earnings Date

2026-11-11

Primary Exchange

NASDAQ

Revenue (USD)

ABEO Revenue (USD) by year
Period	Revenue (USD)
2025	5.82M
2024	0
2023	3.5M
2022	1.41M
2021	3M
2020	10M
2019	0
2018	388K
2017	837K
2016	889K

Net Income (USD)

ABEO Net Income (USD) by year
Period	Net Income (USD)
2025	71.18M
2024	-63.73M
2023	-54.19M
2022	-42.75M
2021	-84.94M
2020	-84.23M
2019	-76.28M
2018	-54.06M
2017	-27.32M
2016	-21.87M

Operating Income (USD)

ABEO Operating Income (USD) by year
Period	Operating Income (USD)
2025	-89.45M
2024	-64.21M
2023	-47.13M
2022	-50.91M
2021	-89.84M
2020	-81.42M
2019	-77.09M
2018	-60.78M
2017	-27.84M
2016	-23.88M

EBITDA (USD)

ABEO EBITDA (USD) by year
Period	EBITDA (USD)
2025	78.59M
2024	-56.62M
2023	-50.57M
2022	-41.81M
2021	-44.76M
2020	-42.76M
2019	-68.44M
2018	-56.91M
2017	-26.57M
2016	-21.04M

Cash Flows (USD)

ABEO Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-84.3M
2024	-58.46M
2023	-37.34M
2022	-43.61M
2021	-69.82M
2020	-36.35M
2019	-69.33M
2018	-58.6M
2017	-23.8M
2016	-13.53M

EPS (USD)

ABEO EPS (USD) by year
Period	EPS (USD)
2025	1.01
2024	-1.88
2023	-2.59
2022	-6.69
2021	-21.13
2020	-22.71
2019	-35.18
2018	-31.06
2017	-16.2
2016	-15.66

Expenses (USD)

ABEO Expenses (USD) by year
Period	Expenses (USD)
2025	99.82M
2024	65.88M
2023	49.7M
2022	47.73M
2021	64.55M
2020	88.17M
2019	77.05M
2018	79.24M
2017	28.79M
2016	24.46M

Cash & Debt (USD)

ABEO Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	191.4M
2024	97.72M
2023	52.23M
2022	52.15M
2021	45.02M
2020	95.03M
2019	129.26M
2018	84.97M
2017	137.75M
2016	69.14M

Debt ratios

ABEO Debt ratios by year
Period	Debt ratios
2025	2.36
2024	0.39
2023	0.26
2022	0.23
2021	0.17
2020	0.44
2019	0.7
2018	0.46

Margins

ABEO Margins by year
Period	Margins
2025	41.15%
2023	33.54%
2022	-1592.01%
2021	-326.77%
2020	-47.87%
2018	-9873.71%
2017	-1929.75%
2016	100%
2015	100%

Return on Capital

ABEO Return on Capital by year
Period	Return on Capital
2025	44.71%
2024	-144.75%
2023	-365.49%
2022	-159.73%
2021	-200.47%
2020	-82.14%
2019	-42.75%
2018	-40.33%
2017	-16.06%
2016	-22.07%

Shares Outstanding

ABEO Shares Outstanding by year
Period	Shares Outstanding
2025	52.95M
2024	41.05M
2023	25.56M
2022	7.14M
2021	4.19M
2020	3.71M
2019	3.71M
2018	1.92M
2017	1.83M
2016	1.61M

Dividends (USD)

ABEO Dividends (USD) by year
Period	Dividends (USD)
2000	3706.25

Employee Count

ABEO Employee Count by year
Period	Employee Count
2025	226
2024	136
2023	84
2022	57
2021	90
2020	76
2019	88
2018	83
2017	42
2016	19

Book Value Per Share (USD)

ABEO Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	3.01
2024	1.07
2023	0.58
2022	3.75
2021	10.12
2020	27.6
2019	48.15
2018	69.89
2017	93.15
2016	61.55

Total Assets (USD)

ABEO Total Assets (USD) by year
Period	Total Assets (USD)
2025	219.57M
2024	108.93M
2023	64M
2022	64.21M
2021	79.59M
2020	151.2M
2019	223.38M
2018	174.4M
2017	178.77M
2016	111.06M

PE Ratio

ABEO PE Ratio by year
Period	PE Ratio
Aug 26	6.2
Jul 26	5.5
Jul 26	5.18
Jul 26	5.99
Jul 26	5.98
Jul 26	5.48
Jun 26	4.8
Jun 26	4.94
Jun 26	4.73
Jun 26	4.67
May 26	4.95
May 26	4.66
May 26	4.7
May 26	4.39
May 26	4.04
Apr 26	4.01
Apr 26	4.09
Apr 26	3.65
Apr 26	3.59
Mar 26	3.19
Mar 26	3.31
Mar 26	3.14
Mar 26	3.19
Feb 26	3.37
Feb 26	3.46
Feb 26	3.3
Feb 26	3.38
Jan 26	3.35
Jan 26	3.4
Jan 26	3.46
Jan 26	3.42
Jan 26	3.5
Dec 25	3.59
Dec 25	3.37
Dec 25	3.53
Dec 25	3.21
Nov 25	3.34
Nov 25	2.95
Nov 25	2.93
Nov 25	3.85
Oct 25	4.41
Oct 25	5.03
Oct 25	4.94
Oct 25	4.92
Oct 25	4.96
Sep 25	4.99
Sep 25	4.94
Sep 25	5.9
Sep 25	6.32
Aug 25	6.27
Aug 25	6.63
Aug 25	6.54

Free Cash Flow Yield

ABEO Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-26.37%
Sep 26	-23.82%
Aug 26	-24.14%
Aug 26	-23.47%
Aug 26	-23.86%
Aug 26	-20.79%
Jul 26	-23.45%
Jul 26	-24.88%
Jul 26	-21.51%
Jul 26	-21.57%
Jul 26	-23.52%
Jun 26	-26.83%
Jun 26	-26.09%
Jun 26	-27.22%
Jun 26	-27.57%
May 26	-26.04%
May 26	-27.67%
May 26	-27.42%
May 26	-26.98%
May 26	-29.32%
Apr 26	-29.54%
Apr 26	-28.95%
Apr 26	-32.42%
Apr 26	-33.03%
Mar 26	-37.11%
Mar 26	-35.78%
Mar 26	-31.9%
Mar 26	-31.31%
Feb 26	-29.66%
Feb 26	-28.87%
Feb 26	-30.31%
Feb 26	-29.6%
Jan 26	-29.83%
Jan 26	-29.43%
Jan 26	-28.92%
Jan 26	-29.26%
Jan 26	-28.59%
Dec 25	-27.86%
Dec 25	-29.71%
Dec 25	-28.33%
Dec 25	-31.18%
Nov 25	-29.95%
Nov 25	-33.89%
Nov 25	-34.12%
Nov 25	-32.32%
Oct 25	-28.22%
Oct 25	-24.77%
Oct 25	-25.23%
Oct 25	-25.32%
Oct 25	-25.09%
Sep 25	-24.95%
Sep 25	-25.23%
Sep 25	-21.11%
Sep 25	-19.7%
Aug 25	-19.87%
Aug 25	-18.77%
Aug 25	-19.04%
Aug 25	-20.22%
Aug 25	-19.5%
Jul 25	-19.38%
Jul 25	-19.21%
Jul 25	-22.05%
Jul 25	-21.49%
Jun 25	-22.01%
Jun 25	-21.49%
Jun 25	-20.55%
Jun 25	-18.78%
May 25	-20.28%
May 25	-19.71%
May 25	-20.75%
May 25	-27.02%
May 25	-21.71%
Apr 25	-26.72%
Apr 25	-29.43%
Apr 25	-30.96%
Apr 25	-31.51%
Mar 25	-28.66%
Mar 25	-27.65%
Mar 25	-19.88%
Mar 25	-20.38%
Feb 25	-20.07%
Feb 25	-18.2%
Feb 25	-17.47%
Feb 25	-18.45%
Jan 25	-18.98%
Jan 25	-19.99%
Jan 25	-20.15%
Jan 25	-18.95%
Jan 25	-17.47%
Dec 24	-18.68%
Dec 24	-18.45%
Dec 24	-17.86%
Dec 24	-17.44%
Nov 24	-16.46%
Nov 24	-17.59%
Nov 24	-17.95%
Nov 24	-17.07%
Nov 24	-17.48%
Oct 24	-16.81%
Oct 24	-16.38%

Price to Sales

ABEO Price to Sales by year
Period	Price to Sales
Sep 26	12.12
Sep 26	13.41
Aug 26	13.23
Aug 26	13.61
Aug 26	13.39
Aug 26	28.19
Jul 26	25
Jul 26	23.56
Jul 26	27.26
Jul 26	27.18
Jul 26	24.92
Jun 26	21.85
Jun 26	22.47
Jun 26	21.53
Jun 26	21.26
May 26	22.51
May 26	21.18
May 26	21.38
May 26	53.68
May 26	49.4
Apr 26	49.04
Apr 26	50.04
Apr 26	44.67
Apr 26	43.85
Mar 26	39.03
Mar 26	40.49
Mar 26	645.49
Mar 26	657.69
Feb 26	694.3
Feb 26	713.29
Feb 26	679.39
Feb 26	695.66
Jan 26	690.24
Jan 26	699.73
Jan 26	711.93
Jan 26	703.8
Jan 26	720.07
Dec 25	739.05
Dec 25	692.95
Dec 25	726.85
Dec 25	660.4
Nov 25	687.52
Nov 25	607.52
Nov 25	603.45
Nov 25	551.51
Oct 25	631.61
Oct 25	719.59
Oct 25	706.45
Oct 25	703.83
Oct 25	710.39
Sep 25	714.33
Sep 25	706.45
Sep 25	844.33
Sep 25	904.73
Aug 25	896.86
Aug 25	949.38
Aug 25	936.25
Aug 24	34.5
Aug 24	36.68
Jul 24	39.8
Jul 24	39.88
Jul 24	43
Jul 24	35.43
Jun 24	33.09
Jun 24	35.74
Jun 24	35.67
Jun 24	33.33
May 24	34.18
May 24	31.69
May 24	34.34
May 24	30.67
May 24	33.59
Apr 24	23.8
Apr 24	55.27
Apr 24	55.13
Apr 24	54.32
Mar 24	52.94
Mar 24	55.57
Mar 24	59.98
Mar 24	55.39
Mar 24	54.28
Feb 24	48.51
Feb 24	48.72
Feb 24	43.09
Feb 24	30.72
Jan 24	32.6
Jan 24	34.75
Jan 24	36.49
Jan 24	39.34
Dec 23	34.82
Dec 23	34.54
Dec 23	33.85
Dec 23	33.22
Dec 23	32.39
Nov 23	29.95
Nov 23	29.12
Nov 23	20.65
Nov 23	22.67
Oct 23	18.74
Oct 23	20.91

EV/EBITDA

ABEO EV/EBITDA by year
Period	EV/EBITDA
Aug 26	3.61
Jul 26	2.97
Jul 26	2.69
Jul 26	3.42
Jul 26	3.41
Jul 26	2.96
Jun 26	2.35
Jun 26	2.47
Jun 26	2.29
Jun 26	2.23
May 26	2.48
May 26	2.22
May 26	2.26
May 26	1.86
May 26	1.54
Apr 26	1.51
Apr 26	1.59
Apr 26	1.19
Apr 26	1.13
Mar 26	0.77
Mar 26	0.88
Mar 26	0.83
Mar 26	0.89
Feb 26	1.05
Feb 26	1.13
Feb 26	0.98
Feb 26	1.06
Jan 26	1.03
Jan 26	1.07
Jan 26	1.13
Jan 26	1.09
Jan 26	1.17
Dec 25	1.25
Dec 25	1.04
Dec 25	1.2
Dec 25	0.9
Nov 25	1.02
Nov 25	0.66
Nov 25	0.65
Nov 25	0.24
Oct 25	0.64
Oct 25	1.08
Oct 25	1.01
Oct 25	1
Oct 25	1.03
Sep 25	1.05
Sep 25	1.01
Sep 25	1.7
Sep 25	2.01
Aug 25	1.97
Aug 25	2.23
Aug 25	2.16

Price to Book

ABEO Price to Book by year
Period	Price to Book
Sep 26	2.41
Sep 26	2.67
Aug 26	2.64
Aug 26	2.71
Aug 26	2.67
Aug 26	2.83
Jul 26	2.51
Jul 26	2.36
Jul 26	2.73
Jul 26	2.73
Jul 26	2.5
Jun 26	2.19
Jun 26	2.25
Jun 26	2.16
Jun 26	2.13
May 26	2.26
May 26	2.13
May 26	2.14
May 26	1.96
May 26	1.81
Apr 26	1.79
Apr 26	1.83
Apr 26	1.63
Apr 26	1.6
Mar 26	1.43
Mar 26	1.48
Mar 26	1.51
Mar 26	1.54
Feb 26	1.62
Feb 26	1.67
Feb 26	1.59
Feb 26	1.63
Jan 26	1.61
Jan 26	1.63
Jan 26	1.66
Jan 26	1.64
Jan 26	1.68
Dec 25	1.73
Dec 25	1.62
Dec 25	1.7
Dec 25	1.54
Nov 25	1.61
Nov 25	1.42
Nov 25	1.41
Nov 25	1.35
Oct 25	1.54
Oct 25	1.76
Oct 25	1.73
Oct 25	1.72
Oct 25	1.74
Sep 25	1.75
Sep 25	1.73
Sep 25	2.06
Sep 25	2.21
Aug 25	2.19
Aug 25	2.32
Aug 25	2.29
Aug 25	7.53
Aug 25	7.8
Jul 25	7.85
Jul 25	7.92
Jul 25	6.9
Jul 25	7.08
Jun 25	6.91
Jun 25	7.08
Jun 25	7.41
Jun 25	8.1
May 25	7.5
May 25	7.72
May 25	7.34
May 25	4.91
May 25	6.12
Apr 25	4.97
Apr 25	4.51
Apr 25	4.29
Apr 25	4.21
Mar 25	4.63
Mar 25	4.8
Mar 25	5.56
Mar 25	5.42
Feb 25	5.5
Feb 25	6.07
Feb 25	6.32
Feb 25	5.99
Jan 25	5.82
Jan 25	5.53
Jan 25	5.48
Jan 25	5.83
Jan 25	6.32
Dec 24	5.91
Dec 24	5.99
Dec 24	6.19
Dec 24	6.33
Nov 24	6.71
Nov 24	6.28
Nov 24	6.16
Nov 24	3.5
Nov 24	3.41
Oct 24	3.55
Oct 24	3.64

No video analysis for this stock yet. Request one from our team.

News: ABEO

prnewswire.com · 10 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).

businesswire.com · 8 Sep 2026

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $ABEO--ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law.

gurufocus.com · 8 Sep 2026

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

globenewswire.com · 8 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

prnewswire.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).

globenewswire.com · 2 Sep 2026

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:

globenewswire.com · 1 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

globenewswire.com · 1 Sep 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

AI Analysis

Abeona Therapeutics Inc.

Video analysis: ABEO

News: ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Similar companies